Navigation Links
Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
Date:3/15/2011

essful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2009, our Form 10-Q for the nine months ended September 30, 2010, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory app
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)... HILL, N.C. , July 31, 2015  In ... of customers who are increasingly mobile, increasingly connected, and ... a growing variety of customer interaction channels and tools ... technology, including social media. According to ... the over the counter (OTC) segment in a call ...
(Date:7/31/2015)...  Seeger Weiss LLP is reporting that on July 13, ... to C.R. Bard, the manufacturer of Inferior vena cava ... violations the agency found at two of Bard,s facilities. Bard ... cited them during Inspectional Observations that occurred on November 18, ... AZ , location and on October 6, 2014, through ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... of its Proprietary Technology to Provide Accurate, Fully ... 34th Annual ISCE MeetingSANTA CLARA, Calif., March 31 ... cardiac diagnostic and services company, today announced that ... abstracts and discuss applications for its proprietary technology ...
... published in the Journal of Medicinal Food, ... (1/3 ounce) of "Sun Chlorella A" daily resulted in ... and fasting blood glucose levels.For a 12-week period, 34 ... each morning and evening. Seventeen subjects were healthy; ...
Cached Medicine Technology:NewCardio Leadership to Present Two Abstracts at ISCE Conference 2NewCardio Leadership to Present Two Abstracts at ISCE Conference 3NewCardio Leadership to Present Two Abstracts at ISCE Conference 4First Human Study to Show 'Sun Chlorella A' Supports Heart Health 2
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
(Date:7/31/2015)... PA (PRWEB) , ... July 31, 2015 , ... M3 ... is excited to launch three new Board Exam Courses. , The additions of ... Doc Board Exam Prep from MDLinx makes preparing for the exam easy and painless. ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... readers and potential patients alike on various plastic surgery procedures including, but not ... include such popular dermatology procedures like Botox and fillers. , Staying up ...
(Date:7/31/2015)... ... 31, 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved ... percent year-over-year for the first six months ended June 30, 2015 compared with the ... beat last year’s record-revenue mark of $10.4 million. , “We know what our customers ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2
... Babies 2008 Official Shoes are Now On Sale, WHITE ... up with Famous Footwear(TM) and Dr. Scholl,s(R) to,introduce the 2008 ... consecutive year, Famous Footwear and Dr. Scholl,s are,raising funds for ... Scholl,s specially designed one men,s and two women,s athletic shoes ...
... Dialysis Corporation,of America (Nasdaq: DCAI ) announced today ... year financial results on March 13, 2008, after the,close ... conference calls,in conjunction with its quarterly earnings releases, beginning ... following morning, March 14,2008 at 10:00 AM EDT., ...
... TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- ... BMY) announced today that the U.S. Food and Drug ... ABILIFY (aripiprazole) for the acute treatment of manic and ... without psychotic features in pediatric patients (10 to 17 ...
... Mojave Desert, Calif., has found that soils under desert pavement ... salt, close to the surface. Vulnerable to erosion by rain ... source of nitrate could contaminate surface and groundwaters, posing an ... March issue of Geology . , Desert pavement is ...
... Japanese Society of Hematology announce a new partnership to ... is available (back to 1997) on Springers online ... a year and was previously published by Carden Jennings. ... is the official journal of the Japanese Society of ...
... of Atlanta, one,of the country,s leading pediatric healthcare ... of pediatric research in Georgia. The,Children,s Board of ... pediatric research., "Annually, income generated from this ... James E. Tally, Ph.D., president and,CEO of Children,s, ...
Cached Medicine News:Health News:Famous Footwear, Dr. Scholl's Step Up to Support March for Babies 2008 2Health News:Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 2Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 3Health News:ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old 4Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 2Health News:Large source of nitrate, a potential water contaminant, found in near-surface desert soils 3Health News:Springer to publish International Journal of Hematology 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 2Health News:Children's Healthcare of Atlanta Announces Major Investment in Pediatric Research as Part of 10-Year Vision 3
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: